Identification of peptide based B-cell epitopes in Zika virus NS1
- Department of Biomedical Science and Engineering, Konkuk University, Seoul, 05029, South (Korea, Republic of)
Highlights: • B-cell epitope mapping in ZIKV NS1. • Identification of the ZIKV NS1 specific antibody binding site. • Tool for design of diagnostics and structure-based vaccine against ZIKV. Zika virus (ZIKV), a mosquito-borne flavivirus that has recently emerged globally, poses a major threat to public health. To control this emerging disease, accurate diagnostics are required for monitoring current ZIKV outbreaks. Owing to the high nucleotide sequence similarity and cross-reactivity of ZIKV with other members of the Flaviviridae family, discrimination from other flavivirus infections is often difficult in endemic areas. ZIKV NS1 induces major virus-specific antibodies and is therefore utilized as a serological marker for ZIKV diagnosis. To identify ZIKV specific epitopes for clinical application, 33 NS1 peptides that are 15–30 amino acid in length covering whole NS1 were synthesized and analyzed linear B-cell epitopes with 38 human serum samples (20 ZIKV-positive and 18 ZIKV-negative). As a result of screening, eight epitope regions were identified. In particular, the Z8 and Z14 peptides located in the β-ladder surface region showed higher levels of binding activity in ZIKV-positive sera without cross-reactivity to other flaviviruses. These identified sensitive and specific epitopes provide a tool for design of diagnostics and structure-based vaccine antigens for ZIKV infection.
- OSTI ID:
- 23100657
- Journal Information:
- Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 4 Vol. 505; ISSN 0006-291X; ISSN BBRCA9
- Country of Publication:
- United States
- Language:
- English
Similar Records
NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice
Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody